In addition to the primary mechanism (i.e., targeting activating mutations in EGFR), several other targets of tyrosine kinase inhibitors including MAPK, and PI3K/AKT have been identified in NSCLC models [24,25,26,27,28,40]. Here, EGFR is linked to non-small cell lung carcinoma.